DIRS.INFO The most relevant business & tech news

☆ Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
▼ + stars: | 2024-06-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +19 min

But other current employees are dissatisfied with where the strategy shift has left them. In January 2023, Pfizer forecast a steep drop in annual revenue, to between $67 billion and $71 billion. Pfizer's 2023 revenue ultimately came in at $58.5 billion, including $11.22 billion from its Covid vaccine and $1.28 billion from Paxlovid. Faith in executive leadership also plunged among some workers, according to most of the current and former employees who spoke with CNBC. Some current workers said that hasn't appeared to change after the town hall on May 2.

Persons: Albert Bourla, Wall, they're, Bourla, I'm, drugmaker Seagen, Irfan Khan, hasn't, Pfizer, renegotiating, John Thys, Payal Sahni Becher, Becher, Kena, Mike McDermott, Bourla's Organizations: Corbis, Getty, Pfizer, Wall, CNBC, Los Angeles Times, Moderna, Centers for Disease Control, U.S ., GSK, Bristol Myers Squibb, Pfizer wasn't, . Biotech, Companies, Biotech, BioNtech, Reuters, Human, View Press, Global, APEC, Summit, Tech, Google Locations: U.S, Covid, Eagle Rock , California, Durham , North Carolina, Puurs, Belgium, New York City, Peapack , New Jersey, Kena

☆ Here are 9 stocks that can benefit from Fed interest rate cuts
▼ + stars: | 2024-06-13 | by ( Zev Fima | ) www.cnbc.com time to read: +7 min

Housing We see Stanley Black & Decker as a major beneficiary of Fed rate cuts due to its link to the housing market. On the one hand, lower rates mean a bank like Wells Fargo makes less money on the money it lends. Biotech Danaher should also see some benefit as lower rates lead to improved funding dynamics for biotech companies. Like in housing, monthly payments become far more manageable at lower rates, and therefore affordability and demand, stand to increase. Salesforce , which has also highlighted more measured deal activity, might not benefit as much from lower rates.

Persons: Jerome Powell, Stanley Black, Decker, Stanley, That's, Wells, Morgan Stanley, SVB, Ford, We're, Jim Cramer's, Jim Cramer, Jim, David Paul Morris Organizations: Nasdaq, CNBC, Fed, Biotech, Silicon Valley Bank, Ford, Palo, Networks, Microsoft, Jim Cramer's Charitable, Bloomberg, Getty Locations: Wells, Wells Fargo, Silicon Valley, Colma , California

☆ Evercore ISI says three years of biotech underperformance may be ending, gives its 5 favorite stocks
▼ + stars: | 2024-05-14 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

"After 3 years of painful underperformance, winter is finally thawing and spring just might be in the air," analyst Cory Kasimov wrote in a Monday note. Biotech stocks broadly peaked in early 2021 when interest rates were at a trough, Kasimov noted. While biotech stocks are sensitive to interest rates, the analyst believes most of the group's other catalysts — such as mergers and access to capital — remain "relatively consistent." XBI YTD mountain SPDR S & P Biotech ETF performance year to date The sector is opportune for investors looking for "a stock picker's market," according to Kasimov. With this in mind, he named seven stocks to his core initial list, which he named "The Magnificent Seven."

Persons: Cory Kasimov, Kasimov, We've, Neurocrine, — CNBC's Michael Bloom Organizations: ISI, Biotech, P Biotech, Moderna Locations: —

☆ Stock futures rise after Apple reports, traders look to April payrolls data: Live updates
▼ + stars: | 2024-05-02 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Futures tied to the Dow Jones Industrial Average gained 212 points, or 0.55%. S&P 500 futures rose nearly 0.3%, while Nasdaq 100 futures advanced about 0.5%. In extended trading, Apple advanced more than 6% after it announced a $110 billion share repurchase and a top -and bottom-line beat. The S&P 500 popped 0.91%, while the Dow gained 0.85%. The S&P 500 is off by 0.7% week to date, while the Nasdaq is down nearly 0.6%.

Persons: Cloudflare, Dow, Jerome Powell, Sonu Varghese, payrolls, Dow Jones Organizations: New York Stock Exchange, Stock, Dow Jones Industrial, Nasdaq, Apple, Biotech Amgen, Dow, Carson Group Locations: New York City, U.S

☆ Citi names 3 biotech stocks to play a growing $2.9 billion opportunity — giving one about 50% upside
▼ + stars: | 2024-05-01 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

The outlook is starting to look bright for biotech stocks, according to some. With markets now expecting the first rate cut to be in September rather than June or July, as previously thought, biotech stocks could start to do well. Biotech encompasses many different areas, but Citi has identified one with a $2.9 billion market — which it says is set for even more growth. It gave CSL a price target of $305, or nearly 11% potential upside. It gave Intellia a price target of $31, or 49% potential upside.

Persons: Morgan Stanley, Garadacimab, Ionis, Citi Organizations: Biotech, Citi, Ionis Pharmaceuticals, Intellia Therapeutics, CSL, Intellia

☆ Danaher shares jump 7% as the turnaround in biotech spending finally arrives
▼ + stars: | 2024-04-23 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Shares of Danaher popped more than 7% on Tuesday after the life sciences company delivered beats across its three main businesses — a sign the long-awaited turnaround in the biotech industry is finally here. Danaher Why we own it : Danaher is a best-in-class life sciences and diagnostics company, with a management team who have proven time and again their ability to find new ways to grow. The turnaround is now in effect, with bioprocessing orders up on a sequential basis. Within the segment, bioprocessing sales fell a "high teens" percentage, while discovery and medical declined 20% year over year. Diagnostics sales advanced 7.5% on a core basis to $2.53 billion.

Persons: Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: LSEG, Bloomberg, Biotechnology, Management, CNBC, Getty Locations: bioprocessing, China, North America, Europe

☆ Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs
▼ + stars: | 2024-04-15 | by ( Christina Jewett | ) www.nytimes.com time to read: +1 min

A Chinese company targeted by members of Congress over potential ties to the Chinese government makes blockbuster drugs for the American market that have been hailed as advances in the treatment of cancers, obesity and debilitating illnesses like cystic fibrosis. WuXi AppTec is one of several companies that lawmakers have identified as potential threats to the security of individual Americans’ genetic information and U.S. intellectual property. A Senate committee approved a bill in March that aides say is intended to push U.S. companies away from doing business with them. The Congressional spotlight on the company has rattled the pharmaceutical industry, which is already struggling with widespread drug shortages now at a 20-year high. Some biotech executives have pushed back, trying to impress on Congress that a sudden decoupling could take some drugs out of the pipeline for years.

Organizations: New York Times Locations: WuXi, U.S

☆ An activist short-seller is making a name for itself by taking on Carl Ichan, Gautam Adani and others
▼ + stars: | 2024-03-19 | by ( Elliot Smith | ) www.cnbc.com time to read: +6 min

Anderson exposes corporate fraud and ponzi schemes through his company Hindenburg Research. Congress (IYC) staged a protest demanding a probe into the allegations of fraud made against the Adani group in the Hindenburg research report. Controversial practice Breakout Point has tracked 74 Hindenburg short bets it has opened since 2017. watch nowBiggest hits One of Hindenburg's biggest recent campaigns centered on a collection of businesses owned by Indian billionaire Gautam Adani. In January 2023, Hindenburg published a report accusing Adani Group companies of "brazen stock manipulation and accounting fraud."

Persons: Nate Anderson, Anderson, Carl Icahn, Gautam Adani, Ivan Cosovic, Hindenburg, LPP, Gautam Organizations: Hindenburg Research, Washington Post, The Washington Post, Getty, The, CNBC, Indian Youth Congress, Central, Indian Youth Congress Office, Congress, Hindustan Times, GameStop, Hindenburg's, Adani, Securities and Exchange Board of India Locations: The New York, NY, New York, DELHI, India, New Delhi, Gdansk, Russia, Ukraine

☆ Wall Street sees a better backdrop for IPOs. Great news for these 2 portfolio stocks
▼ + stars: | 2024-02-12 | by ( Morgan Chittum | ) www.cnbc.com time to read: +5 min

Wall Street is forecasting a better backdrop for companies that want to go public. While lower rates can stoke the IPO market, fewer rate cuts because the economy remains strong with cooling inflation should still be viewed as favorable. The IPO market and mergers and acquisitions (M & A) activity started to sour when the Fed began hiking interest rates back in March 2022. A strong IPO market overall is expected to also benefit burgeoning biotechnology firms, which would mean more business for Danaher. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: That's, Goldman Sachs, Goldman, Morgan Stanley, Danaher, Morgan, Morgan Stanley didn't, Ted Pick's, Jim Cramer, Morgan Stanley's, Raymond James, —, Jim Cramer's, Jim, Brendan Mcdermid Organizations: Federal, stoke, UST, Goldman, Fed, Companies, IB, Danaher, Biotech, Silicon Valley Bank, CNBC, Traders, New York Stock Exchange Locations: U.S, Silicon

☆ Danaher shares hit a 1-year high after earnings and we're increasing our price target
▼ + stars: | 2024-01-30 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

DHR 1Y mountain Danaher 1 year Shares of Danaher rose as much as 5% to a 52-week high of $245.40 each. Core sales, not shown on the table, were down 22.5%. Core sales were down 4% year over year as strength from academic and life science research customers was more than offset by weakness from pharma and biopharma customers. Core sales fell about the same as strength in clinical diagnostics, driven by Beckman Coulter Diagnostics was more than offset by lower respiratory revenue at Cepheid. In this photo illustration, Danaher Corporation logo is seen displayed on a smartphone and PC screen.

Persons: we've, Danaher, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: Revenue, LSEG, JPMorgan Healthcare, Sciences, Diagnostics, Biotechnology, Management, pharma, Beckman Coulter Diagnostics, CNBC, Getty Locations: Danaher, China, Biotechnology, North America, Europe, Asia, Pacific, Cepheid

☆ Frustrated by healthcare's failings, the rich are investing in biotech to live longer and healthier
▼ + stars: | 2024-01-30 | by ( Hayley Cuccinello | ) www.businessinsider.com time to read: +8 min

AdvertisementWinter is part of a growing group of family office principals, including heirs like himself and first-generation entrepreneurs, who are making direct investments in pursuit of longer and healthier lives. They are in good company; longevity startups drew global investment of more than $5.2 billion in 2022 , according to a venture capital firm, Longevity Tech Fund, which used PitchBook data. She and some of her clients are investors in Maximon, a Switzerland-based longevity fund that includes "healthspan clinics" in its portfolio. Eric Becker, cofounder of wealth manager Cresset , and his two sons founded a family office and picked Blue Zone Foods as its first investment. Courtesy of CressetFor Becker, whose daughter died of leukemia at 21, and his family, longevity is not an abstract topic.

Persons: Maximilian Winter, doggedly, Lyme, Fritz Winter, Peter Thiel, There's, Peter Fioretti, David Sinclair, Kathrin Genovese, ultrarich, Genovese, Eric Becker, Cresset, Dan Yadegar, Becker, Johnny Walker Organizations: Longevity Tech Fund, Harmonix, Biotech, UBS, Winter's Harmonix Fund, Blue, Foods, Becker Venture Partners, Newpath Partners Locations: Santa Barbara, Quinta , California, Maximon, Switzerland, Zurich

LONDON (AP) — Amazon called off its purchase of robot vacuum maker iRobot on Monday, blaming “undue and disproportionate regulatory hurdles" after the European Union signaled its objection to the deal. The deal faced antitrust scrutiny on both sides of the Atlantic, but most strongly in Europe, where regulators investigating competition concerns were expected to issue a final decision by Feb. 14. Amazon announced in 2022 that it would buy iRobot, maker of the circular-shaped Roomba vacuum, for $1.7 billion in cash. Political Cartoons View All 253 ImagesWhile British antitrust regulators cleared the purchase in June, it also still faced scrutiny in the U.S. by the Federal Trade Commission. This is the latest example of a deal involving U.S. companies that fell apart after facing scrutiny from European regulators.

Persons: iRobot, David Zapolsky, Amazon’s, Colin Angle, Glen Weinstein, Haleluya Hadero Organizations: European Union, Amazon, European Commission, Federal Trade Commission, U.S, Adobe, Biotech, ___ AP Locations: European, Europe, Bedford , Massachusetts, U.S, EU, New York

ROCK RAPIDS, Iowa (AP) — Some of the most contested real estate for Iowa's Republican caucuses is a vast, wind-swept plain where hogs outnumber people by the millions. Ron DeSantis have invested in appealing to politically influential evangelicals, making the fight for northwest Iowa a microcosm of the race to win Monday's caucuses. DeSantis has spent long hours courting voters here, stopping Thursday in Rock Rapids, population 2,600, before heading to Le Mars, about four times larger. Texas Sen. Ted Cruz, with his social conservative brand, competed strongly for northwest Iowa in 2016 and edged Trump in the region on his way to a narrow caucus victory. Ambassador Nikki Haley, aiming for a surprise second-place finish in Iowa, has campaigned in northwest Iowa, but less often and to smaller audiences.

Persons: Donald Trump, Ron DeSantis, DeSantis, that's, he’s, ”, John Vermeer, “, ” Vermeer, Trump, Texas Sen, Ted Cruz, Pennsylvania Sen, Rick Santorum, Mike Huckabee’s, Nikki Haley, Vivek Ramaswamy, Randy Vande Berg, Roe, Wade, He's, Vande Berg, Republican underperformance, “ It's, There's, Heidi Kock Organizations: ROCK, Republican, telltale, Florida Gov, Trump, Reformed Church, Texas, Arkansas Gov, Sioux Center, U.N, Biotech, U.S, Supreme Locations: ROCK RAPIDS, Iowa, Rock Rapids, Le, Netherlands, Florida, Pennsylvania, Iowa's, Sioux, Sioux County, Monday's

BRUSSELS (AP) — The European Union on Thursday ordered U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators in the 27-nation bloc. The EU already slapped a $475 million fine on Illumina over the summer for jumping the gun on the acquisition without its consent. Allowing the deal to stand would have undermined the credibility of EU regulators. The EU accused Illumina and Grail of knowingly and deliberately merging before getting clearance in what amounted to a vital infringement of the rules. Illumina must “restore the situation prevailing before” the acquisition, regulators said, and how Illumina divests itself of Grail also needs EU approval.

Persons: Didier Reynders, Illumina, ”, Grail Organizations: Union, Thursday, EU, Companies, European Commission, Illumina, Regulators, Federal Trade Commission Locations: BRUSSELS, EU, U.S, San Diego

☆ Rising interest rates are hurting very broad swaths of the stock and bond markets
▼ + stars: | 2023-10-03 | by ( Bob Pisani | ) www.cnbc.com time to read: +3 min

Dozens of stocks and ETFs are hitting 52-week lows on the relentless rise in interest rates. Treasury bond ETFs: New lows iShares 1-3 Year Treasury Bond ETF (SHY) iShares 7-10 Year Treasury Bond ETF (IEF) iShares 10-20 Year Treasury Bond ETF (TLH) iShares 20+ Year Treasury Bond ETF (TLT) It's not just Treasury bonds. Broad bond ETFs: New lows Vanguard Total Bond Market ETF (BND) iShares Core US Aggregate Bond Fund (AGG) Higher rates are affecting other areas of the U.S. economy: look at clean energy and biotech It's simple. Clean energy ETFs: New lows iShares Global Clean Energy (ICLN) VanEck Low Carbon Energy ETF (SMOG) Invesco WilderHill Clean Energy ETF (PBW) Invesco Solar ETF (TAN) It's the same story with biotech. The SPDR S & P Biotech ETF (XBI) , which tracks an equal-weighted index of US biotechnology stocks, is at a 52-week low.

Persons: Schwab, It's Organizations: Vanguard Utilities, Treasury Bond ETF, Bond Market, Bond Fund, NextEra Energy Partners, Clean Energy, Carbon Energy, P Biotech, Biotechnology, Biotech, Verizon, SPDR Telecom, AT, Property, Comerica, Huntington Bancshares Locations: U.S, Orsted, Denmark, REITs

☆ SolarEdge is among the most oversold stocks in the S&P 500. Here are the others
▼ + stars: | 2023-08-12 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

Following this week's moves, CNBC Pro used FactSet data to screen for the most overbought and oversold names in the S & P 500 based on their 14-day relative strength index, or RSI. Here are some of the most oversold names: SolarEdge is one of the most oversold companies in the S & P 500. NextEra Energy had the highest number of analyst buy ratings among the stocks on the oversold list, according to CNBC's screen. Meanwhile, the following 10 stocks are the most overbought in the S & P 500: Marathon Petroleum is the most overbought stock in the broad-based index, with an RSI of 96.3. Oilfield servicer Halliburton Company , Cessna aircraft maker Textron and construction services provider Jacobs Solutions are also among the most overbought companies in the S & P 500.

Persons: Dow Jones Industrials, SolarEdge Organizations: SolarEdge Technologies, Nasdaq, Nvidia, Micron, CNBC Pro, Street, NextEra Energy, Moderna, GE Healthcare Technologies, Ameren Corporation, Enphase Energy, Marathon Petroleum, Biotech, Global Payments, Jefferies, servicer Halliburton Company, Cessna, Textron, Jacobs Solutions Locations: Florida, Cambridge , Massachusetts

☆ 'Harder to find': Goldman Sachs names stocks with growth at a 'reasonable' price — and more
▼ + stars: | 2023-07-27 | by ( Weizhen Tan | ) www.cnbc.com time to read: +3 min

Stocks with "reasonably valued" growth are becoming harder to find — given the increasing overlap between high-growth and expensive stocks, according to Goldman Sachs. First screen The first focused on stocks with growth at a reasonable price. SolarEdge Technologies : Investors can also look for strong growth from favorable geographic and end-market exposure. "Its refreshed, modern restaurant POS [point of sale] platform and new verticals should drive market share growth," Goldman analysts wrote. "We believe margins will remain in focus through 2023 and into 2024," Goldman said.

Persons: Goldman Sachs, Goldman, Goldman's, Johnson, Michael Bloom Organizations: Technologies, SolarEdge, BioMarin Pharmaceutical, Constellation Brands Locations: Europe, U.S

☆ Using AI to monitor orphaned elephants in Botswana could usher in the return of the woolly mammoth
▼ + stars: | 2023-07-19 | by ( Tom Page | ) edition.cnn.com time to read: +7 min

The startup has entered a collaboration with Elephant Havens, a wildlife foundation based in the Okavango Delta that cares for orphaned elephants. The findings, the organizations hope, could provide a blueprint for releasing the elephants into the wild and mammoth hybrids to the tundra. A new system for elephant monitoringHuman-wildlife conflict is the leading cause of elephant orphans in Botswana, says Elephant Havens founder Debra Stevens. After five years in the enclosure, Elephant Havens will reintroduce these bonded herds into the wild, and monitor their progress for a decade. Biotech company Colossal wants to create a hybrid combining mammoth DNA with that of Asian elephants.

Persons: “, –, Elephant, We’ll, ”, Matt James, Debra Stevens, “ That’s, Stevens, revel, Havens, Steve Metzler, Dr, Wendy Kiso, James, Debra, ” James, Ben Lamm, ” Lamm, Lamm Organizations: CNN, Colossal Biosciences, Biotech company Colossal, Colossal Locations: Botswana, Africa, rewilding, America

☆ CNBC Pro Talks: Fund manager to reveal his top tech picks, says 'big is beautiful' in the sector right now
▼ + stars: | 2023-07-18 | by ( Cnbc.Com Staff | ) www.cnbc.com time to read: +2 min

From Alphabet to Meta , Richard Clode, portfolio manager at Janus Henderson Investors, is a fan of Big Tech — but his interest in the sector goes beyond the behemoths. Clode, who manages the Horizon Global Technology Leaders Fund and the Horizon Sustainable Future Technologies Fund, will reveal how he selects stocks that he judges to be underappreciated by the market. Top holdings in his funds include chipmakers Nvidia and TSMC , payments giants Mastercard and Visa and a range of Big Tech stocks. Join CNBC Pro Talks here on Wednesday, June 19, at 1:30 p.m. SGT / 6:30 a.m. BST / 1:30 a.m. Learn more from our previous Pro Talks: This U.S. biotech stock is up 90% this year and will continue to soar, fund manager says Aging populations are creating major opportunities, fund manager says.

Persons: Richard Clode, Janus Henderson, Koulouris, Clode, Goldman Sachs Organizations: Janus Henderson Investors, Big Tech, Horizon Global Technology, Fund, Technologies Fund, Nvidia, Mastercard, Visa, Nasdaq, Global Technology, Technologies, Moore, Pioneer Investments, Pro, UBS Locations: Gartmore

☆ Weight loss without Wegovy’s side-effects on biotech firms' radar
▼ + stars: | 2023-07-07 | by ( Maggie Fick | ) www.reuters.com time to read: +8 min

It leads to 22.5% weight loss, according to a Lilly trial published last year. The effect achieves far more weight loss than predecessors. An even earlier stage biotech firm, Antag Therapeutics in Denmark, told Reuters that the ballooning obesity market has improved its fundraising prospects. It curbs appetite by restoring the natural release of GLP-1 and other hormones, without causing nausea, Phase I data showed. The effect of the drug on weight loss is being tested in the Phase II study.

Persons: Rebecca Vogt, Handout, Wegovy, Vogt, Jayson Dallas, Noushin Irani, Mounjaro, Eli Lilly's, Lilly, Andrew Levin, Rivus, Mark Fineman, Ashish Nimgaonkar, Nimgaonkar, Alexander Sparre, Ulrich, Tim Opler, Opler, Stifel, Maggie Fick, Josephine Mason, Daniel Flynn Organizations: REUTERS, Nordisk's, Food and Drug Administration, U.S, Reuters, Rivus Pharmaceuticals, Investors, Deutsche, FDA, Pfizer, Capital Management, Rivus, Therapeutics, Johns Hopkins University, pharma, Antag Therapeutics, Aphaia Pharma, Thomson Locations: Irving , New York, U.S, GLP, Buffalo , New York, United States, Dallas, Baltimore , Maryland, Denmark, Switzerland

☆ Focus: Biotech firms target weight-loss drugs without Wegovy's side-effects
▼ + stars: | 2023-07-07 | by ( Maggie Fick | ) www.reuters.com time to read: +8 min

[1/7] Rebecca Vogt, a former user of the weight-loss drug Wegovy, poses for a photo, in Irving, New York, U.S., June 20, 2023. It leads to 22.5% weight loss, according to a Lilly trial published last year. An even earlier stage biotech firm, Antag Therapeutics in Denmark, told Reuters that the ballooning obesity market has improved its fundraising prospects. It curbs appetite by restoring the natural release of GLP-1 and other hormones, without causing nausea, Phase I data showed. The effect of the drug on weight loss is being tested in the Phase II study.

☆ This U.S. biotech stock is up 90% this year and will continue to soar, fund manager says
▼ + stars: | 2023-06-23 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

Shares of U.S. biotech firm Exact Sciences have surged by almost 90% this year. But the run may not be over just yet, according to fund manager Dani Saurymper. Earlier this week it said its next-generation screening test, Cologuard 2.0, showed a 30% lower false positive rate for detecting the disease in a study compared to its already approved test. This is where Exact Sciences fits in. Saurymper believes that the stock has corrected and has a significant runway ahead.

Persons: Dani Saurymper, Saurymper, CNBC's, EXAS, Kyle Mikson, Canaccord Genuity, CNBC's Arabile, it's Organizations: Sciences, Nasdaq, Companies, FDA

☆ Novartis buys Chinook for $3.5 bln in race to treat rare kidney disease
▼ + stars: | 2023-06-12 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

June 12 (Reuters) - Novartis (NOVN.S) said it has agreed to acquire U.S. biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment. The other drug hopeful is iptacopan, which is being trialled against a number of rare genetic disorders, including IgAN and another kidney disease. IgAN is a progressive autoimmune disease that mostly affects young adults and which can lead to kidney failure that requires dialysis or organ transplantation. IgAN is the most common cause of kidney failure in Caucasian young adults, Novartis added. Additional reporting by Miranda Murray; Editing by Kim Coghill, Sonali Paul and Alexander SmithOur Standards: The Thomson Reuters Trust Principles.

Persons: Novartis, Vas Narasimhan, Narasimham, atrasentan, Narasimhan, Kisqali, Roche, Vera, Muddy Waters, Miranda Murray, Kim Coghill, Sonali Paul, Alexander Smith Organizations: Novartis, Chinook Therapeutics, Vera Therapeutics, Sandoz, Chinook, Thomson Locations: Seattle, United States

☆ This beaten-down sector could be a bright spot in commercial real estate
▼ + stars: | 2023-06-06 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +6 min

As the market reassesses the value of office properties, investors have been steering clear of many commercial real estate stocks. Greg Kuhl, a portfolio manager at Janus Henderson, said he likes the outlook for Alexandria Real Estate Equities , a pure-play owner of life sciences centers. Malhotra said he sees lab REITs as a "lower-beta way to play the volatile Life Sciences environment." But each of these companies are more broadly diversified and have exposure to other types of commercial real estate. Kilroy, for example, had been focused in properties in the tech hubs, but it now has a growing life sciences portfolio.

Persons: Greg Kuhl, Janus Henderson, Kuhl, hasn't, Vikram Malhotra, Mizuho, Malhotra, Healthpeak's, Kilroy Organizations: Alexandria Real, stoke, Food and Drug Administration, Research, Biotech, Sciences, iShares Biotechnology, Boston Properties, Kilroy Locations: Alexandria, Ventas

☆ Lab-grown breast milk startup Biomilq aims to change infant nutrition — if it can release a product
▼ + stars: | 2023-05-20 | by ( Natasha Piñon | ) www.cnbc.com time to read: +11 min

Biomilq, the company behind the breakthrough, had been working for nearly a decade to replicate the process of making human milk — but outside of the body. While the crisis has highlighted the importance of a resilient formula supply, human milk experts, milk bank advocates and Biomilq all stress the same message: Breast milk is best. The startup will likely take a "gradual approach" to introducing its science via "an early-life nutrition product in partnership with one of these bigger companies," Strickland explained. Breast milk is woefully understudied — to the point that it's difficult "to even say what human milk is from a nutritional standpoint," Perrin explained. The company is researching which aspects of human milk its system is best suited to produce.

Search resuls for: ". Biotech"

25 mentions found